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Abstract
Prognosis in colon cancer is based on pathological criteria including TNM staging. However, there are deﬁciencies in this approach,
and the lymph node ratio (LNR) has been proposed to improve the prediction of outcomes. LNR is dependent on optimal retrieval of
lymph nodes—lymph node count (LNC). Recent studies have suggested that an elevated preoperative systemic inﬂammatory
response (SIR) was associated with a lower LNC and a higher LNR. However, there are a number of potential confounding factors.
The aim of the present study was to examine, in detail, these relationships in a large cohort of patients.
A prospectively maintained database of all patients undergoing colon cancer resection in our institution was examined. The SIR
was measured by a number of inﬂammatory markers and their scores: modiﬁed Glasgow Prognostic Score (mGPS) (C-reactive
protein/albumin), neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), and lymphocyte monocyte ratio (LMR) using
standard thresholds. The relationships between LNC and LNR, and clinicopathological characteristics (including the mGPS, NLR,
PLR, and LMR) were examined using chi-square test for trend and binary logistic regression analysis, where appropriate.
Of the 896 patients included in the study, 418 (47%) were male, the median LNC was 17 (1–71), and the median LNR in node
positive disease was 0.16 (0.03–1). On multivariate analysis, there was a signiﬁcant independent relationship between an elevated
LNC (≥12) and laparoscopic surgery (P< .001), right-sided tumors (P< .001), later date of resection (2007–2016) (P< .001), T stage
(P< .001), and venous invasion (P< .001). In those patients with a LNC ≥12 and node-positive disease (n=272), on multivariate
analysis, there was a signiﬁcant relationship between an elevated LNR (≥0.25), and T stage (P< .01) and differentiation (P< .05).
Finally, in patients with node-positive disease who had surgery later (2007–2016), LNR was directly superior to N stage for both
cancer-speciﬁc survival (LNR: hazard ratio [HR] 2.62, 95% conﬁdence interval [CI] 1.25–5.52, P= .011) and overall survival (LNR: HR
2.02, 95% CI 1.12–3.68, P= .022).
Neither LNC nor LNR was associated with markers of the SIR; however, LNC and LNR were directly associated. In high-quality
surgical and pathological practice, LNR had superior prognostic value compared with N stage in patients undergoing surgery for
colon cancer.
Abbreviations: CRP=C-reactive protein, LMR= lymphocytemonocyte ratio, LNC= lymph node count, LNR= lymph node ratio,
mGPS =modiﬁed Glasgow Prognostic Score, NLR = neutrophil lymphyocyte ratio, OS = overall survival, PLR = platelet lymphocyte
ratio, SIR = systemic inﬂammatory response, TNM = tumor node metastasis.
Keywords: cancer speciﬁc survival, inﬂammation, lymph node count, lymph node ratio, lymphocyte monocyte ratio, modiﬁed
Glasgow Prognostic Score, neutrophil lymphocyte ratio, overall survival, platelet lymphocyte ratio1. Introduction
Cancer remains 1 of the leading causes of death worldwide and is
responsible for 7.6 million deaths per year.[1–3] In the UnitedEditor: Xiao-Dong Chen.
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1Kingdom, it is responsible for at least 50,000 deaths each year in
the 35 to 64-year age groups, and in their lifetime, 1 in 3 will
develop cancer, and 1 in 4 will die from it.[1] In potentially
curative disease, surgical resection is the treatment of choice and
prognosis is signiﬁcantly based on clinicopathological criteria,
including the TNM staging system, which divides patients into
groups based on tumor invasion, local nodal involvement, and
distant metastatic spread.[4]
A high lymph node count (LNC) at resection has been reported
to be associated with improved outcomes, regardless of tumor
stage, with a LNC of≥12 been widely accepted as indicative of an
oncologically sound surgical resection.[5,6] The prognostic value
of LNC would appear to be dependent on node-positive disease,
because an increase in the proportion of positive nodes (lymph
node ratio [LNR]) within any given resected specimen is strongly
associatedwith poorer outcomes, with the cut-off value of 0.25 (1
in 4 nodes positive) having particular signiﬁcance.[4,7,8] However,
with variable retrieval of lymph nodes from surgical specimens
LNR has not been incorporated into routine tumor staging.
Over the past 15 years, it has become clear that disease
progression and cancer is not just dependent on local tumor
factors, but rather on a complex interaction of both tumor and
[9,10]
Dolan et al. Medicine (2018) 97:13 Medicinethe host inﬂammatory responses. Local tumor responses in
colorectal cancer can be assessed by lymphocytic inﬁltration with
improved survival in those who express a local lymphocytic
response.[11,12] Also, the systemic inﬂammatory response (SIR)
can be assessed by combined prognostic scores such as modiﬁed
Glasgow Prognostic Score (mGPS) (C-reactive protein [CRP]
and albumin), neutrophil lymphocyte ratio (NLR), platelet
lymphocyte ratio (PLR), and lymphocyte monocyte ratio
(LMR).[1,10,13,14]
Therefore, it is of interest that an elevated SIR in patients with
colon cancer (n=303)[4] and in colorectal cancer (n=501)[15] has
been reported to be associated with a lower LNC. Also, an
elevated SIR was associated with an increased LNR and poorer
survival.[4] These studies would suggest that the SIR may result in
a lower LNCwith a consequent increase in the LNRwith a direct
impact on survival.[4]
Therefore, the primary aim of the present study was to
examine, in detail, the relationships between LNC and LNR, and
clinicopathological characteristics (including markers of SIR), in
a large cohort of patients undergoing surgery for colon cancer.
The secondary aim of this study was to assess the impact of both
LNC and LNR on survival. No previous studies have
comprehensively examined combination markers of the SIR in
relation to both LNC and LNR in such a large cohort of patients
undergoing surgery for colorectal cancer.2. Patients and methods
Patients were identiﬁed from a prospectively collected and
maintained database of colon cancer resections undertaken in a
single surgical unit at Glasgow Royal Inﬁrmary. In the present
study, there were 2 main inclusion criteria, namely patients who,
on the basis of preoperative abdominal computed tomography
and laparotomy ﬁndings, were considered to have undergone
potentially curative resection for colonic cancer between
January, 1997 and May, 2016, and patients who had
preoperative measurement of serum CRP, albumin, and
differential blood cell counts within 30 days before surgery.
Due to the prospective nature of the database, less than 10% of
patients were excluded from the study. In particular, those
patients with documented underlying inﬂammatory conditions,
inﬂammatory bowel disease-related cancer, and, who underwent
resection with palliative intent or local resection only, or had not
had preoperative measurement of CRP or albumin, were
excluded from the analysis. Tumors were staged using the ﬁfth
edition of the TNM, with additional data taken from
pathological reports issued after resection.[16] The ﬁfth edition
of the TNM staging was used as per pathological practice in
Glasgow Royal Inﬁrmary. After surgery, all patients were
discussed at a multidisciplinary meeting involving surgeons,
oncologists, radiologists, and pathologists with special interest in
colorectal cancer; patients with stage III or high-risk stage II
disease and no signiﬁcant comorbidities precluding chemothera-
py use were offered primarily 5-ﬂuorouracil-based adjuvant
chemotherapy on the basis of current guidelines at the time. A
LNC ≥12 was used in this study as it has been reported in the
literature as been indicative of an adequate and safe surgical
resectionwith improved outcomes.[5,6] A LNR≥0.25was used in
this study, as it has been reported in the literature and has been
associated with a higher tumor load associated with poorer
outcomes.[4,7,8]
Preoperative serum CRP, albumin, and differential blood
cell counts were recorded prospectively. Patients undergoing2resection, serum CRP, albumin, and differential blood cell counts
were measured routinely within 30 days before surgery. The
mGPS[1] was constructed as previously described (patients with a
CRP 10mg/L were allocated a score of 0, a CRP >10mg/L a
score of 1, and a CRP >10mg/L and albumin <35g/L a score of
2). NLR, PLR, and LMR were all calculated by directly dividing
the former by the latter.
Patients were routinely followed up for 5 years after surgery.
Date and cause of death were crosschecked with the cancer
registration system and the Registrar General (Scotland). Death
records were complete until May 31, 2016, which acted as the
censor date. Cancer-speciﬁc survival was measured from date
of surgery until date of death from recurrent or metastatic
colonic cancer, and was expressed as a percentage with an
associated standard error with signiﬁcance been assessed using
a log-rank P test. Overall survival (OS) was measured until the
date of death from any cause, and was expressed as a
percentage with an associated standard error with signiﬁcance
been assessed using a log-rank P test. Lymph node size was not
assessed formally in this study, and consultant pathologists
assessed all pathological specimens to ensure consistency. The
West of Scotland Research Ethics Committee approved the
study.
The primary endpoint of examining the relationships
between LNC and LNR, and clinicopathological characteristics
(including the mGPS, NLR, PLR, and LMR) was examined
using chi-square test for trend and binary logistic regression
analysis. To adjust for multiple comparisons, a P value of
<0.01 was considered signiﬁcant. All characteristics that were
statistically signiﬁcant on chi-square test were entered into
univariate binary logistic regression for both LNC and LNR.
Clinicopathological factors associated with the LNC and LNR
on univariate analysis that had a P value <0.05 were taken into
a multivariate model using a backward conditional model to
identify independently signiﬁcant factors. The secondary
endpoint of examining the relationship between LNC and
LNR, and survival was examined using a log-rank P test.
Statistical analysis was performed using SPSS version 22.0
(IBM Corp, Armonk, NY).3. Results
Of the 896 patients included in the study, 418 (47%) were male,
478 (53%) female, the median LNC was 17 (1–71), and the
median LNR in node-positive disease was 0.16 (0.03–1). The was
a signiﬁcant association between LNC and LNR (r=0.379,
P< .001; Fig. 1)
The relationship between the LNC (<12/≥12), clinicopatho-
logical characteristics, markers of the SIR, LNR, and survival in
patients undergoing surgery for colon cancer is shown in Table 1.
LNC ≥12 (n=676) was signiﬁcantly associated with no ischemic
heart disease (n=132, P= .001), laparoscopic surgery (n=148,
P< .001), surgery carried out between 2007 and 2016 (n=444,
P< .001), right-sided tumors (n=383, P< .001), higher T stage
(n=581, P< .001), and venous invasion (n=378, P< .001).
LNC ≥12 was not signiﬁcantly associated with any of the
markers of the SIR or with improved cancer speciﬁc (P= .176), or
OS (P= .296). LNC≥12 was signiﬁcantly associated with a lower
LNR (n=613, P= .001).
Binary logistic regression analysis was carried out on those
variables with a signiﬁcant association with LNC<12/≥12
(Table 2). On multivariate analysis, there was a signiﬁcant
independent relationship between an elevated LNC (≥12) and
Figure 1. The relationship between LNC and LNR in patients with a positive lymph node in patients undergoing surgery for colon cancer (n=377, r=0.379,
P< .001). LNC= lymph node count, LNR= lymph node ratio.
Table 1
The relationship between the LNC (<12/≥12), clinicopathological characteristics, LNR and survival in patients undergoing surgery for
colon cancer (n=896).
Colon (n=896) (%)
Patient factors LNC <12 (n=220) (%) LNC ≥12 (n=676) (%) P
Age (<65/65–74/>75 y) 61 (27.7)/67 (30.5)/92 (41.8) 225 (33.3)/237 (35.1)/214 (31.7) .022
Sex (F/M) 99 (45.0)/121 (55.0) 319 (47.2)/357 (52.8) .572
Elective/emergency 197 (90.4)/21 (9.6) 577 (85.6)/97 (14.4) .072
BMI
1 (underweight) 15 (9.5) 54 (10.1) .016
2 (normal) 55 (34.8) 168 (31.4)
3 (overweight) 60 (38.0) 154 (28.8)
4 (obese) 28 (72.7) 159 (29.7)
ASA
1 20 (10.8) 108 (17.9) .046
2 78 (42.2) 263 (43.5)
3 79 (42.7) 202 (33.4)
4 8 (4.3) 31 (5.1)
Smoker
Never 85 (44.5) 313 (50.9) .302
Ex 73 (38.2) 206 (33.5)
Current 33 (17.3) 96 (15.6)
IHD
No 106 (63.9) 441 (77.0) .001
Yes 60 (36.1) 132 (23.0)
CVA/TIA
No 128 (88.3) 480 (89.4) .703
Yes 17 (11.7) 57 (10.6)
PVD
No 139 (95.9) 513 (95.7) .935
Yes 6 (4.1) 23 (4.3)
(continued )
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Table 1
(continued).
Colon (n=896) (%)
Patient factors LNC <12 (n=220) (%) LNC ≥12 (n=676) (%) P
COPD
No 152 (83.5) 528 (89.6) .025
Yes 30 (16.5) 61 (10.4)
Asthma
No 163 (90.1) 531 (90.5) .872
Yes 18 (9.9) 56 (9.5)
Diabetes
No 115 (78.8) 448 (83.6) .174
Yes 31 (21.2) 88 (16.4)
Surgery
Open 197 (91.6) 518 (77.8) <.001
Laparoscopic 18 (8.4) 148 (22.2)
1997–2006 122 (55.5) 232 (34.3) <.001
2007–2016 98 (44.5) 444 (65.7)
Tumor factors
Tumor site (left) 92 (51.4) 170 (30.7) <.001
Tumor site (right) 87 (48.6) 383 (69.4)
T stage (1) 29 (13.2) 33 (4.9) <.001
T stage (2) 30 (13.6) 62 (9.2)
T stage (3) 91 (41.4) 378 (55.9)
T stage (4) 70 (31.8) 203 (30.0)
N stage (0) 143 (65.0) 404 (59.8) .017
N stage (1) 65 (29.5) 189 (28.0)
N stage (2) 12 (5.5) 83 (12.3)
Differentiation
Well/moderate 196 (90.7) 603 (89.9) .220
Poor 20 (9.3) 68 (10.1)
Venous invasion
No 132 (60.0) 298 (44.1) <.001
Yes 88 (40.0) 378 (55.9)
Margin involvement
No 199 (90.9) 632 (93.6) .165
Yes 20 (9.1) 43 (6.4)
Peritoneal involvement
No 166 (75.8) 509 (76.1) .843
Yes 53 (24.2) 159 (23.8)
Tumor perforation
No 208 (95.0) 656 (97.2) .094
Yes 10 (4.6) 19 (2.8)
Neoadjuvant therapy
No 214 (97.3) 667 (99.3) .021
Yes 6 (2.7) 5 (0.7)
Systemic inﬂammation
mGPS 0 141 (64.1) 421 (62.3) .735
mGPS 1 45 (20.5) 135 (20.0)
mGPS 2 34 (15.5) 120 (17.8)
NLR <5 129 (84.3) 442 (81.3) .385
NLR ≥5 24 (15.7) 102 (18.8)
PLR <150 50 (45.5) 164 (35.6) .055
PLR ≥150 60 (54.5) 297 (64.4)
LMR >2.4 49 (64.5) 239 (59.2) .386
LMR 2.4 27 (35.5) 165 (40.8)
Lymph node ratio (<0.25/≥0.25) 182 (82.7)/38 (17.3) 613 (90.7)/63 (9.3) .001
Cancer-speciﬁc survival (% and SE) 77% (3% SE) 78% (2% SE) .176
Overall survival (% and SE) 64% (3% SE) 67% (2% SE) .296
ASA=American Society of Anaesthesiologist Classiﬁcation, BMI=body mass index, COPD=chronic obstructive pulmonary disease, CVA= cerebral vascular disease, IHD= ischemic heart disease, LMR=
lymphocyte monocyte ratio, mGPS=modiﬁed Glasgow Prognostic Score, NLR=neutrophil lymphocyte ratio, PLR=platelet lymphocyte ratio, PVD=peripheral vascular disease, SE= standard error, TIA=
transient ischemic attack.
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Table 2
The relationship between the LNC (<12/≥12), clinicopathological characteristics, and LNR in patients undergoing surgery for colon cancer
(binary logistic regression analysis).
Univariate 95% Conﬁdence interval Multivariate 95% Conﬁdence interval
n=896 OR Lower Upper P OR Lower Upper P
IHD 1.891 1.304 2.742 .001 1.372 0.884 2.130 .158
Lap/open 0.320 0.191 0.536 <.001 0.409 0.205 0.817 .011
Dates (97–06 vs 06–16) 0.420 0.308 0.572 <.001 0.341 0.219 0.533 <.001
Right vs left 0.420 0.297 0.592 <.001 0.572 0.380 0.860 .007
T stage 0.761 0.636 0.910 .003 0.511 0.394 0.664 <.001
Venous invasion 0.526 0.386 0.716 <.001 0.761 0.486 1.191 .232
LNR (≥0.25) 2.032 1.315 3.139 .001 2.247 1.216 4.152 .010
IHD= ischemic heart disease, LNR= lymph node ratio, OR= odds ratio.
Dolan et al. Medicine (2018) 97:13 www.md-journal.comlaparoscopic surgery (P< .05), right-sided tumors (P< .01),
surgery carried out between 2007 and 2016 (P< .001), T stage
(P< .001), and LNR ≥0.25 (P< .05).
In those patients who had a LNC ≥12 and a LNR >0, the
relationship between the LNR (<0.25/≥0.25), and clinicopatho-
logical characteristics and survival in patients undergoing surgery
for colon cancer is shown in Table 3. LNR ≥0.25 (n=63) was
signiﬁcantly associated with higher T stage (n=62, P< .01),
poorer differentiation (n=12, P< .01), and peritoneal involve-Table 3
The relationship between the LNR (<0.25/≥0.25), clinicopathological ch
cancer and with a resectional lymph node count of ≥12 and a LNR >
Colon lymph nod
Patient factor LNR 0.01–0.249 (n=209) (%
Age (<65/65–74/>75) 78 (37.3)/61 (29.2)/70 (33.5
Sex (F/M) 94 (45.0)/115 (55.0)
Elective/emergency 173 (83.6)/34 (16.4)
BMI
1 (underweight) 17 (10.6)
2 (normal) 44 (27.3)
3 (overweight) 56 (34.8)
4 (obese) 44 (27.3)
ASA
1 35 (19.3)
2 74 (40.9)
3 63 (34.8)
4 9 (5.0)
Smoker
Never 104 (53.6)
Ex 67 (34.5)
Current 23 (11.9)
IHD
No 140 (76.9)
Yes 42 (23.1)
CVA/TIA
No 150 (88.8)
Yes 19 (11.2)
PVD
No 162 (96.4)
Yes 6 (3.6)
COPD
No 172 (92.0)
Yes 15 (8.0)
Asthma
No 166 (89.2)
Yes 20 (10.8)
5ment (n=30, P< .01). LNR ≥0.25 was not signiﬁcantly
associated with any of the markers of the SIR. LNR ≥0.25
was signiﬁcantly associated with poorer cancer-speciﬁc survival
(P= .002) and OS (P= .048).
Binary logistic regression analysis was carried out on those
variableswith a signiﬁcant associationwith LNR≥0.25 (Table 4).
On multivariate analysis, there was a signiﬁcant independent
relationship between an elevated LNR (≥0.25) and T stage
(P< .01).aracteristics, and survival in patients undergoing surgery for colon
0 (n=272).
e count ≥12 and LNR >0 (n=272) (%)
) LNR ≥0.25 (n=63) (%) P
) 17 (27.0)/30 (47.6)/16 (25.4) .025
31 (49.2)/32 (50.8) .556
46 (73.0)/17 (27.0) .061
4 (8.2) .713
14 (28.6)
14 (28.6)
17 (34.7)
7 (11.1) .097
22 (39.3)
19 (33.9)
8 (14.3)
31 (56.4) .841
17 (30.9)
7 (12.7)
37 (68.5) .211
17 (31.5)
38 (84.4) .432
7 (15.6)
41 (91.1) .135
4 (8.9)
48 (90.6) .743
5 (9.4)
44 (83.0) .222
9 (17.0)
(continued )
Table 3
(continued).
Colon lymph node count ≥12 and LNR >0 (n=272) (%)
Patient factor LNR 0.01–0.249 (n=209) (%) LNR ≥0.25 (n=63) (%) P
Diabetes
No 141 (83.9) 34 (75.6) .194
Yes 27 (16.1) 11 (24.4)
Surgery
Open 164 (78.8) 50 (80.6) .760
Laparoscopic 44 (21.2) 12 (19.4)
1997–2006 74 (35.4) 27 (42.9) .284
2007–2016 135 (64.6) 36 (57.1)
Tumor factors
Tumor site (right) 113 (70.2) 36 (65.5) .513
Tumor site (left) 48 (29.8) 19 (34.5)
T stage (1) 3 (1.4) 1 (1.6) .005
T stage (2) 9 (4.3) 0 (0)
T stage (3) 112 (53.6) 21 (33.3)
T stage (4) 85 (40.7) 41 (65.1)
Differentiation
Well/moderate 188 (90.8) 51 (81.0) .005
Poor 19 (9.2) 12 (19.0)
Venous invasion
No 69 (33.0) 15 (23.8) .166
Yes 140 (67.0) 48 (76.2)
Margin involvement
No 188 (90.0) 51 (82.3) .100
Yes 21 (10.0) 11 (17.7)
Peritoneal involvement
No 141 (68.8) 30 (50.0) .008
Yes 64 (31.2) 30 (50.0)
Tumor perforation
No 200 (96.2) 63 (100.0) .115
Yes 8 (3.8) 0 (0)
Neoadjuvant therapy
No 206 (98.6) 61 (98.4) .231
Yes 3 (1.4) 1 (1.6)
Systemic inﬂammation
mGPS 0 130 (62.2) 34 (54.0) .500
mGPS 1 42 (20.1) 15 (23.8)
mGPS 2 37 (17.7) 14 (22.2)
NLR <5 137 (80.1) 35 (76.1) .550
NLR ≥5 34 (19.9) 11 (23.9)
PLR <150 51 (34.2) 12 (31.6) .758
PLR ≥150 98 (65.8) 26 (68.4)
LMR >2.4 73 (57.5) 16 (48.5) .356
LMR 2.4 54 (42.5) 17 (51.5)
Cancer-speciﬁc survival (% and SE) 71% (4% SE) 50% (7% SE) .002
Overall survival (% and SE) 60% (4% SE) 44% (7% SE) .048
ASA=American Society of Anaesthesiologist Classiﬁcation, BMI=body mass index, COPD=chronic obstructive pulmonary disease, CVA= cerebral vascular disease, IHD= ischemic heart disease, LMR=
lymphocyte monocyte ratio, mGPS=modiﬁed Glasgow Prognostic Score, NLR=neutrophil lymphocyte ratio, PLR=platelet lymphocyte ratio, PVD=peripheral vascular disease, SE= standard error, TIA=
transient ischemic attack.
Table 4
The relationship between the LNR (<0.25/≥0.25) and clinicopathological characteristics in patients undergoing surgery for colon cancer
and with a resectional lymph node count of ≥12 and a LNR >0 (n=272) (binary logistic regression analysis).
Univariate 95% Conﬁdence interval Multivariate 95% Conﬁdence interval
n=272 OR Lower Upper P Odds ratio (OR) Lower Upper P
T stage 2.327 1.367 3.962 .002 2.257 1.229 4.144 .009
Differentiation 2.328 1.061 5.110 .035 2.560 1.010 6.488 .048
Peritoneal involvement 2.206 0.728 6.682 .162
Dolan et al. Medicine (2018) 97:13 Medicine
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The results of the present study conﬁrm that the LNR is dependent
on the LNCandhas prognostic value in patientswith colon cancer.
The present study does not conﬁrm the reported relationship
between the LNC and LNR, and the SIR, as measured by mGPS,
NLR,PLR, andLMR.Therefore, the present results donot support
the proposal that a SIR in colon cancer results in lymph node
hypertrophy leading to a lower LNC and a higher LNR.[4,15] In
contrast, the present results highlight the importance of T stage,
and high-quality surgery and pathology in ensuring optimal
assessment of nodal spread in patients with colon cancer.
There is now good evidence that, after resection of colon
cancer, a LNC of 12 or greater provides for a better
characterization of nodal status.[6] Indeed, consistent with the
present results LNCs of below 12 correlate with poor outcomes,
and this has been largely explained by variances in the quality of
surgical and pathological practice.[17,18] However, there remains
doubt whether such a lymph node retrieval benchmark can be
achieved in all resected colon cancer specimens.[19,20]
The LNR has repeatedly been reported as an effective
stratiﬁcation factor in patients with node-positive colorectal
cancer. However, as shown in the present study, it is critically
dependent on the quality of pathology performed, in particular,
lymph node retrieval, and this limitation has precluded
incorporation into routine clinical staging. In the present study,
the quality benchmark of 12 or more nodes retrieved was
conﬁrmed to be independently associated with laparoscopic
surgery, right-sided tumors, more invasive tumors, and the period
of surgery. With reference to the latter, 12 or more nodes
retrieved improved from 34% in 1997 to 2006, to 66% in 2007
to 2016, and when this benchmark was achieved, the LNR was
similar in the 2 time periods. Given the improvement in meeting
this benchmark, it may be that the LNR is now a suitable
replacement for N stage in patients with colon cancer. Indeed, in
the later period (2007–2016) when the prognostic value of LNR
and N stage were directly compared in node-positive disease,
LNR had superior prognostic value for both cancer-speciﬁc
survival (LNR: hazard ratio [HR] 2.62, 95% conﬁdence interval
[CI] 1.25–5.52, P= .011; N stage: HR 1.22, 95% CI 0.83–1.80,
P= .308) and OS (LNR: HR 2.02, 95% CI 1.12–3.68, P= .022;
N stage: HR 1.09, 95% CI 0.82–1.46, P= .552). Therefore, with
high-quality surgery and pathology, LNR offers additional
prognostic value in patients with colon cancer, and may be a
more useful measure to guide adjuvant therapy.
When the benchmark of ≥12 nodes retrieved/examined was
met in node-positive disease only T stage was an independent
determinant of the LNR. These results conﬁrm the importance of
tumor invasiveness in the process of lymph node spread and
staging of colon cancer. Therefore, where there is suboptimal
retrieval of lymph nodes after surgery for colon cancer, there is a
case that patients with T3/T4 stage should be considered at high
risk of recurrence.
The main limitation of the present study was that it is a
retrospective analysis. However, it was carried out on a
prospectively collected dataset, and the cohort size was
substantial, with detailed information on the clinicopathological
characteristics of the patients included.
5. Conclusions
In summary, the results of the present study conﬁrm that the LNR is
dependent on the LNC, and has prognostic value in patients with
colon cancer. The present study does not conﬁrm the reported7relationship between the LNC and LNR, and the SIR, as measured
by mGPS, NLR, PLR, and LMR. In high-quality surgical and
pathological practice,LNRhas superior prognosticvalue compared
with N stage in patients undergoing surgery for colon cancer.
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